Leading BioSciences Announces Potential for Investigational Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients

    NEXT STORY
    CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
    PREV STORY
    Tauriga Sciences Inc. and Aegea Biotechnologies Inc. Enter into Collaboration Agreement to Develop a Rapid, Multiplexed Novel Coronavirus (COVID-19) Test Designed to Exhibit Superior Performance
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering

    author_avatar
    NASDAQ Market News

    BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

    author_avatar
    NASDAQ Market News

    Coherus Secures Private Placement from Temasek

    REDWOOD CITY, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today ...

    author_avatar
    NASDAQ Market News